Nerve Growth Factor and Pain  

Oleh:

Wood, John N.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 363 no. 16 (Nov. 2010), page 1572-1573.
Topik: PAIN; rowth facto

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K.2010.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Osteoarthritis, a common, painful condition, occurs at a rate of 1% per year and affects the majority of people who are over 55 years of age. In a proof-of-concept, phase 2 study in this issue of the Journal, Lane and colleagues1 report that blocking the activity of nerve growth factor with a neutralizing humanized monoclonal antibody (tanezumab) can relieve pain from osteoarthritis. This finding raises the possibility of using neutralizing antibodies therapeutically, similar to the use of antibodies against tumor necrosis factor (TNF) in patients with rheumatoid arthritis. However, recent results of a phase 3 study, mentioned by Lane et al. in the Discussion section of their article, indicate that although tanezumab has analgesic efficacy, it precipitates joint failure in some recipients. Accordingly, at the request of the Food and Drug Administration (FDA), a number of clinical trials with tanezumab have been suspended.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali